{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Define subjects who experienced toxicities associated with this treatment regimen","groups":[{"description":"Cyclophosphamide, fludarabine, total body irradiation, immune suppression including tacrolimus and cellcept, Granulocyte colony-stimulating factor (G-CSF), and peripheral blood transplant\n\nCyclophosphamide: 14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)\n\nFludarabine: 30 mg/m2 daily for 5 days\n\nTotal Body Irradiation: 200 centigray (cGy) for one day (day -1)\n\nTacrolimus: 1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.\n\ncellcept: dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.\n\ng-csf: 5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) \\> 1000/mcL for 3 days.\n\nPeripheral Blood Transplant: cell dose goal: \\< 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight","id":"OG000","title":"Johns Hopkins' Conditioning Regimen"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Post-peripheral blood transplant","title":"Number of Participants Who Experienced Toxicities Associated With This Treatment Regimen","type":"PRIMARY","unitOfMeasure":"Participants"}